36 completed, 8 active not recruiting, 4 recruiting, 4 terminated. 59 Phase 3, 4 Phase 2.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 59 | Completed 36, Active not recruiting 8, Recruiting 4, Terminated 4, Unknown 3, Not yet recruiting 2, Enrolling by invitation 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 1, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Trials (filtered) newest first · largest first
All 59 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | 382 | 2026-09-21 | 2026-11-09 |
Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
Autologous whole blood therapy, Desloratadine - Chronic Idiopathic Urticaria | Phase 3 | Not yet recruiting | 40 | 2026-04-30 | 2026-03-20 |
A Study of MG-K10 in Chronic Spontaneous Urticaria
MG-K10 Humanized Monoclonal Antibody Injection, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Not yet recruiting | 226 | 2026-04-14 | 2026-04-22 |
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
JYB1904, Placebo+JYB1904 - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | 240 | 2026-03-09 | 2026-08-03 |
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
ICP-332 Tablets, ICP-332 placebo Tablets - Chronic Spontaneous Urticaria (CSU) | Phase 2 / Phase 3 | Recruiting | 344 | 2026-02-13 | 2026-04-21 |
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Barzolvolimab, Matching Placebo - Chronic Inducible Urticaria, Cold Urticaria | Phase 3 | Recruiting | 240 | 2026-01-15 | 2026-11-02 |
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
barzolvolimab, Standard of Care - Chronic Spontaneous Urticaria | Phase 3 | Enrolling by invitation | 1370 | 2025-11-25 | 2026-11-02 |
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Remibrutinib, Remibrutinib matching placebo, Dupilumab - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Active not recruiting | 409 | 2025-07-11 | 2026-11-09 |
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | 976 | 2024-07-19 | 2026-03-25 |
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | 963 | 2024-07-11 | 2026-03-25 |
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
CMAB007, Xolair - Chronic Spontaneous Urticaria | Phase 3 | Completed | 392 | 2024-06-18 | 2026-10-02 |
A Study of Efficacy and Safety of TLL-018 in CSU Participants
TLL-018 tablets, Placebo tablets - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | 440 | 2024-03-27 | 2026-06-03 |
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
Remibrutinib, Placebo - Chronic Inducible Urticaria | Phase 3 | Active not recruiting | 362 | 2023-12-07 | 2026-10-15 |
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
Remibrutinib, Placebo to remibrutinib, Placebo to omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | 470 | 2023-11-15 | 2026-10-14 |
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
Omalizumab Injection, Xolair Prefilled Syringe - Chronic Idiopathic Urticaria | Phase 3 | Completed | 600 | 2023-08-15 | 2025-02-05 |
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
LOU064 (blinded), placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | 100 | 2023-07-11 | 2026-10-15 |
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
LOU064 - Chronic Spontaneous Urticaria | Phase 3 | Completed | 144 | 2023-04-05 | 2025-10-16 |
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
LOU064 (blinded), Placebo, LOU064 (open label) - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | 696 | 2022-12-09 | 2026-03-11 |
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
Dupilumab - Chronic Spontaneous Urticaria | Phase 3 | Completed | 15 | 2022-08-25 | 2025-11-25 |
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
LOU064 - Chronic Spontaneous Urticaria | Phase 3 | Completed | 71 | 2022-01-15 | 2025-04-08 |
Showing 20 of 59. Sign in to see all of them.
Narrower conditions
Cryopyrin-Associated Periodic Syndromes (9) · Urticaria (6) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Chronic Inducible Urticaria (3) · Cold Urticaria (3) · Angioedema (2) · Familial dermographism (2) · Hypersensitivity (2) · Pruritus (2) · Rhinitis, Allergic (2) · Rhinitis, Allergic, Seasonal (2) · Arthralgia (1) · Arthritis, Juvenile (1) · Bronchiolitis Obliterans Syndrome (1)
Broader conditions
Chronic Disease (59) · Disease Attributes (59) · Hypersensitivity, Immediate (59) · Immune System Diseases (59) · Pathologic Processes (59) · Pathological Conditions, Signs and Symptoms (59) · Skin Diseases (59) · Skin Diseases, Vascular (59) · Skin and Connective Tissue Diseases (59) · Hypersensitivity (57) · Urticaria (53) · Chronic Inducible Urticaria (9) · Cold Urticaria (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)
Interventions
Omalizumab (17) · remibrutinib (10) · canakinumab (8) · ligelizumab (5) · desloratadine (3) · dupilumab (3) · levocetirizine (3) · Injections (2) · Control Groups (1) · Diphenhydramine (1) · Etanercept (1) · Histamine Antagonists (1) · Leukotriene Antagonists (1) · Methotrexate (1) · Standard of Care (1)
Sponsors
Novartis Pharmaceuticals (24) · Celldex Therapeutics (4) · Charite University, Berlin, Germany (3) · Genentech, Inc. (3) · Novartis (2) · Sanofi (2) · UCB Pharma (2) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · Cairo University (1) · Celltrion (1) · Chang Gung Memorial Hospital (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Hospices Civils de Lyon (1) · Insel Gruppe AG, University Hospital Bern (1)
Countries
United States (29) · Germany (25) · Spain (21) · France (19) · Canada (18) · Poland (16) · United Kingdom (16) · Argentina (13) · India (13) · Italy (13) · Turkey (Türkiye) (13) · Japan (12) · China (11) · Hungary (10) · Slovakia (10)
Top investigators
Cheng Zhou (1) · Christopher Hull, MD (1) · Edward R. Conner, M.D. (1) · Hui Tang, PhD (1) · Jianzhong Zhang (1) · Jinhua Xu, PhD (1) · Karsten Weller, MD (1) · Marcus Maurer, MD (1)
Results publications
PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 20819318, PMID 31161734, PMID 38008109, PMID 39193419, PMID 40043237, PMID 42297099, PMID 18668535, PMID 19494217, PMID 21859692, PMID 22152723, PMID 23031624, PMID 23053062, PMID 23380020, PMID 23432142, PMID 24906637, PMID 25046337, PMID 27010957, PMID 30618764, PMID 32272284, PMID 33865434, PMID 39066978, PMID 41272364, PMID 41326897, PMID 41706458, PMID 41712058, PMID 41847564, PMID 41854973
NIH funding
2018 (2), 2019 (2), 2009 (1), 2014 (1), 2015 (1), 2023 (1)